IGC Valuation

IGC Pharma Inc

Add to Watchlist

Advanced Chart

0.412

+0.003(0.733%)1D

Overview
Forecast
Valuation
Earnings

IGC Relative Valuation

IGC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IGC is overvalued; if below, it's undervalued.

Historical Valuation

IGC Pharma Inc (IGC) is now in the Overvalued zone, suggesting that its current forward PS ratio of 27.26 is considered Overvalued compared with the five-year average of -1.35. The fair price of IGC Pharma Inc (IGC) is between 0.24 to 0.33 according to relative valuation methord. Compared to the current price of 0.41 USD , IGC Pharma Inc is Overvalued By 22.14%.

Relative Value

Fair Zone

0.24-0.33

Current Price：0.41

22.14%

Overvalued

-5.11

Trailing

Forward

0.00

EV/EBITDA

IGC Pharma Inc. (IGC) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-5.09

EV/EBIT

IGC Pharma Inc. (IGC) has a current EV/EBIT of -5.09. The 5-year average EV/EBIT is -0.32. The thresholds are as follows: Strongly Undervalued below -5.49, Undervalued between -5.49 and -2.90, Fairly Valued between 2.27 and -2.90, Overvalued between 2.27 and 4.85, and Strongly Overvalued above 4.85. The current Forward EV/EBIT of -5.09 falls within the Undervalued range.

27.26

IGC Pharma Inc. (IGC) has a current PS of 27.26. The 5-year average PS is 9.86. The thresholds are as follows: Strongly Undervalued below -12.31, Undervalued between -12.31 and -1.23, Fairly Valued between 20.94 and -1.23, Overvalued between 20.94 and 32.03, and Strongly Overvalued above 32.03. The current Forward PS of 27.26 falls within the Overvalued range.

-8.15

P/OCF

IGC Pharma Inc. (IGC) has a current P/OCF of -8.15. The 5-year average P/OCF is -1.99. The thresholds are as follows: Strongly Undervalued below -6.41, Undervalued between -6.41 and -4.20, Fairly Valued between 0.22 and -4.20, Overvalued between 0.22 and 2.43, and Strongly Overvalued above 2.43. The current Forward P/OCF of -8.15 falls within the Strongly Undervalued range.

0.00

P/FCF

IGC Pharma Inc. (IGC) has a current P/FCF of 0.00. The 5-year average P/FCF is 1.46. The thresholds are as follows: Strongly Undervalued below -3.05, Undervalued between -3.05 and -0.79, Fairly Valued between 3.72 and -0.79, Overvalued between 3.72 and 5.97, and Strongly Overvalued above 5.97. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

IGC Pharma Inc (IGC) has a current Price-to-Book (P/B) ratio of 5.66. Compared to its 3-year average P/B ratio of 2.71 , the current P/B ratio is approximately 108.96% higher. Relative to its 5-year average P/B ratio of 2.49, the current P/B ratio is about 127.24% higher. IGC Pharma Inc (IGC) has a Forward Free Cash Flow (FCF) yield of approximately -11.59%. Compared to its 3-year average FCF yield of -26.73%, the current FCF yield is approximately -56.63% lower. Relative to its 5-year average FCF yield of -23.80% , the current FCF yield is about -51.29% lower.

5.66

P/B

Median3y

2.71

Median5y

2.49

-11.59

FCF Yield

Median3y

-26.73

Median5y

-23.80

Competitors Valuation Multiple

The average P/S ratio for IGC's competitors is 11.00, providing a benchmark for relative valuation. IGC Pharma Inc Corp (IGC) exhibits a P/S ratio of 27.26, which is 147.82% above the industry average. Given its robust revenue growth of 20.59%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Rani Therapeutics Holdings Inc

Loss

34.58M

MRSN.O

Mersana Therapeutics Inc

Senti Biosciences Inc

Performance Decomposition

Market capitalization of IGC increased by 11.32% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -3.80 to -5.14.

The secondary factor is the Revenue Growth, contributed 20.59%to the performance.

Overall, the performance of IGC in the past 1 year is driven by P/E Change. Which is more unsustainable.

20.59%

272.00K → 328.00K

Revenue Growth

-44.24%

-874.26 → -487.50

Margin Expansion

34.97%

-3.80 → -5.14

P/E Change

11.32%